Comparison of the effects of chlormadinone acetate versus drospirenone containing oral contraceptives on metabolic and hormonal parameters in women with PCOS for a period of two-year follow-up

References

• Cascella T, Palomba S, De Sio I, et al. Visceral fat is associated with cardiovascular risk in women with polycystic ovary syndrome. Hum Reprod 2008;23:153–9
   PubMed Web of Science ®Google Scholar
• Orio F, Vuolo L, Palomba S, et al. Metabolic and cardiovascular consequences of polycystic ovary syndrome. Minerva Ginecol 2008;60:39–51
   PubMedGoogle Scholar
• Ovalle F, Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril 2002;77:1095–105
   PubMed Web of Science ®Google Scholar
• Ehrmann DA, Liljenquist DR, Kasza K, et al.; PCOS/Troglitazone Study Group. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:48–53
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care l99l;l4:173–94
   Google Scholar
• Azziz R, Carmina E, Dewailly D, et al. Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. J Clin Endocrinol Metab 2006;91:4237–45
   PubMed Web of Science ®Google Scholar
• Sung YA, Oh JY, Chung H, Lee H. Hyperandrogenemia is implicated in both the metabolic and reproductive morbidities of polycystic ovary syndrome. Fertil Steril 2014;101:840–5
   PubMed Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM–Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19–25
   Web of Science ®Google Scholar
• Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 1981;140:815–30
   PubMed Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–9
   PubMed Web of Science ®Google Scholar
• Gallo MF, Lopez LM, Grimes DA, et al. Combination contraceptives: effects on weight. Cochrane Database Syst Rev 2014;1:CD003987
   PubMedGoogle Scholar
• Lello S, Primavera G, Colonna L, et al. Effects of two estroprogestins containing ethynilestradiol 30 microg and drospirenone 3 mg and ethynilestradiol 30 microg and chlormadinone 2 mg on skin and hormonal hyperandrogenic manifestations. Gynecol Endocrinol 2008;24:718–23
   PubMed Web of Science ®Google Scholar
• Bhattacharya SM, Jha A. Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome. Fertil Steril 2012;98:1053–9
   PubMed Web of Science ®Google Scholar
• Guido M, Romualdi D, Giuliani M, et al. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab 2004;89:2817–23
   PubMed Web of Science ®Google Scholar
• Ibáñez L, de Zegher F. Ethinylestradiol-drospirenone, flutamide–metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. J Clin Endocrinol Metab 2004;89:1592–7
   PubMed Web of Science ®Google Scholar
• Torkzahrani S, Heidari A, Mostafavi-Pour Z, et al. Amelioration of lipid abnormalities by vitamin therapy in women using oral contraceptives. Clin Exp Reprod Med 2014;41:15–20
   Google Scholar
• Mes-Krowinkel MG, Louwers YV, Mulders AG, et al. Influence of oral contraceptives on anthropomorphometric, endocrine, and metabolic profiles of anovulatory polycystic ovary syndrome patients. Fertil Steril 2014;101:1757–65
   PubMed Web of Science ®Google Scholar
• Morin-Papunen L, Rautio K, Ruokonen A, et al. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:4649–54
   PubMed Web of Science ®Google Scholar
• Yilmaz Ö, Calan O, Kume T, Calan M. The relationship of urotensin II with insulin resistance and hs-CRP in patients having PCOS. Gynecol Endocrinol 2013;29:970–3
   PubMed Web of Science ®Google Scholar
• Shanik MH, Xu Y, Skrha J, et al. Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse? Diabetes Care 2008;31:S262–8
   PubMed Web of Science ®Google Scholar
• Fruzzetti F, Perini D, Lazzarini V, et al. Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome. Fertil Steril 2010;94:1793–8
   PubMed Web of Science ®Google Scholar
• Bouchard P. Chlormadinone acetate (CMA) in oral contraception—a new opportunity. Eur J Contracept Reprod Health Care 2005;10:7–13
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R. Pharmacological profile of progestins. Maturitas 2008;61:151–7
   PubMed Web of Science ®Google Scholar
• Kraus D, Jäger J, Meier B, et al. Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes. Horm Metab Res 2005;37:455–9
   PubMed Web of Science ®Google Scholar
• Corry DB, Tuck ML. The effect of aldosterone on glucose metabolism. Curr Hypertens Rep 2003;5:106–9
   PubMed Web of Science ®Google Scholar
• De Leo V, Di Sabatino A, Musacchio MC, et al. Effect of oral contraceptives on markers of hyperandrogenism and SHBG in women with polycystic ovary syndrome. Contraception 2010;82:276–80
   PubMed Web of Science ®Google Scholar
• Lerchbaum E, Schwetz V, Giuliani A, et al. Opposing effects of dehydroepiandrosterone sulfate and free testosterone on metabolic phenotype in women with polycystic ovary syndrome. Fertil Steril 2012;98:1318–25
   PubMed Web of Science ®Google Scholar
• Luque-Ramírez M, Alpañés M, Escobar-Morreale HF. The determinants of insulin sensitivity, β-cell function, and glucose tolerance are different in patients with polycystic ovary syndrome than in women who do not have hyperandrogenism. Fertil Steril 2010;94:2214–21
   PubMed Web of Science ®Google Scholar